What is TB-500?
TB-500 is a research peptide based on a fragment of thymosin beta-4, a naturally occurring protein found in nearly all human cells. Researchers have studied thymosin beta-4 in preclinical models for actin regulation and cellular migration signaling — the studied processes that underlie tissue-repair research.
What has the research literature examined?
Published research on TB-500 and thymosin beta-4 fragments includes preclinical work in cardiac tissue, corneal tissue, and dermal wound models. Reviewers consistently note that translation to controlled human clinical trials is limited. Secondary sources marketing dramatic human outcomes should be cross-checked against primary PubMed literature.
How is TB-500 discussed in athletic communities?
Athletic community references to TB-500 typically involve informal discussion of soft-tissue recovery signaling. These references are anecdotal, not clinical evidence, and are not equivalent to a use recommendation or endorsement of any protocol.
Regulatory and WADA status
TB-500 (thymosin beta-4 fragments) has been referenced in WADA prohibited categories in past cycles. Any competitive athlete considering education about this compound must independently verify the current WADA Prohibited List. TB-500 is not FDA-approved for human use.
Safety considerations documented in the literature
Key safety variables include: purity of unregulated research-chemical supply, absence of long-term human safety data, potential for interaction with other pharmacological agents, and jurisdictional legal risk. None of these variables can be assessed without professional medical and legal counsel.